FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study

Atherosclerosis

Volumn 222, Issue 1, 2012, Pages 229-234

  Cabré, Anna ^a,b   Babio, Nancy ^b,c   Lázaro, Iolanda ^a,b   Bulló, Mònica ^b,c   Garcia Arellano, Ana ^d   Masana, Lluís ^a,b   Salas Salvadó, Jordi ^b,c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Atherogenic dyslipidemia; FABP4; Predictive marker; PREDIMED

Indexed keywords

FATTY ACID BINDING PROTEIN 4; INSULIN;

ADULT; AGED; ARTICLE; ATHEROGENIC DYSLIPIDEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; INSULIN BLOOD LEVEL; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE;

AGED; ATHEROSCLEROSIS; DYSLIPIDEMIAS; FATTY ACID-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PREDICTIVE VALUE OF TESTS;

EID: 84859879370     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.02.003     Document Type: Article

References (23)

1. Taskinen M.R. Type 2 diabetes as a lipid disorder. Curr Mol Med 2005, 5:297-308.
2. Soysal A., Demiral Y., Soysal D., Ucku R., Koseoglu M., Aksakoglu G. The prevalence of metabolic syndrome among young adults in Izmir, Turkey. Anadolu Kardiyol Derg 2005, 5:196-201.
3. Adiels M., Taskinen M.R., Packard C., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006, 49:755-765.
4. Chan D.C., Watts G.F. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin Pharmacother 2011, 12:13-30.
5. Fisher E.A. GPIHBP1: lipoprotein lipase's ticket to ride. Cell Metab 2010, 12:1-2.
6. Scheja L., Makowski L., Uysal K.T., et al. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999, 48:1987-1994.
7. Hotamisligil G.S., Johnson R.S., Distel R.J., Ellis R., Papaioannou V.E., Spiegelman B.M. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996, 274:1377-1379.
8. Makowski L., Boord J.B., Maeda K., et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001, 7:699-705.
9. Shen W.J., Liang Y., Hong R., et al. Characterization of the functional interaction of adipocyte lipid-binding protein with hormone-sensitive lipase. J Biol Chem 2001, 276:49443-49448.
10. Xu A., Wang Y., Xu J.Y., et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006, 52:405-413.
11. Cabré A., Lázaro I., Girona J., et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007, 195:e150-e158.
12. Coll B., Cabré A., Alonso-Villaverde C., et al. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis 2008, 199:147-153.
13. Hu W.H., Qiao J., Li R., Wang L.N. Relations of serum adipocyte fatty acid binding protein to sex hormone and lipoproteins in patients with polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi 2006, 86:3186-3189.
14. Koh J.H., Shin Y.G., Nam S.M., Lee M.Y., Chung C.H., Shin J.Y. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diabetes Care 2009, 32:147-152.
15. Xu A., Tso A.W., Cheung B.M., et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007, 115:1537-1543.
16. Tso A.W., Xu A., Sham P.C., et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007, 30:2667-2672.
17. Yeung D.C.Y., Xu A., Cheung C.W.S., Wat N.M.S., Yau M.H., Fong CHYet al. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:1796-1802.
18. Cabré A., Lázaro I., Girona J., et al. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res 2008, 49:1746-1751.
19. Estruch R., Martínez-González M.A., Corella D., et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006, 145:1-11.
20. Salas-Salvadó J., Fernández-Ballart J., Ros E., et al. Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year results of the PREDIMED randomized trial. Arch Intern Med 2008, 168:2449-2458.
21. Martínez-González M.A., Corella D., Salas-Salvadó J., et al. Cohort profile: design and methods of the PREDIMED study. Int J Epidemiol 2010, [E-pub ahead of print 20.12.10]. 10.1093/ije/dyq250.
22. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
23. Fisher R.M., Eriksson P., Hoffstedt J., et al. Fatty acid binding protein expression in different adipose tissue depots from lean and obese individuals. Diabetologia 2001, 44:1268-1273.